Anthracycline chemotherapy significantly reduced CMR left ventricular ejection fraction from 61% at baseline to 53% at completion of treatment, with baseline MAPSE and specific miRNAs predicting poor recovery.
Cohort (n=24)
Blinded analysis of imaging data
Yes
Do baseline CMR parameters and circulating MicroRNAs predict LVEF recovery in patients receiving anthracycline chemotherapy?
Baseline CMR-derived MAPSE and specific circulating miRNAs (miRNA-181-5p, miRNA-221-3p) may serve as early predictors for poor LVEF recovery following anthracycline chemotherapy.
Absolute Event Rate: 53% vs 61%
p-value: p=<0.001
Background: Anthracycline cardiotoxicity is a significant clinical challenge. Biomarkers to improve risk stratification and identify early cardiac injury are required. Objectives: The purpose of this pilot study was to prospectively characterize anthracycline cardiotoxicity using cardiovascular magnetic resonance (CMR), echocardiography and MicroRNAs (MiRNAs), and identify baseline predictors of LVEF recovery. Methods: doxorubicin equivalent) were recruited and evaluated at three timepoints (baseline, completion of chemotherapy, and 6 months after completion of chemotherapy) with multiparametric 1.5 T CMR, echocardiography and circulating miRNAs sequencing. Results: mapping or late gadolinium enhancement were observed. Conclusions: Baseline CMR-derived MAPSE, circulating miRNA-181-5p, and miRNA-221-3p were associated with poor recovery of LVEF 6 months after completion of anthracycline chemotherapy, suggesting their potential predictive role in this context. T2 mapping increased significantly on completion of chemotherapy but was not predictive of LVEF recovery.
Harries et al. (Tue,) conducted a cohort in Haematological malignancy scheduled for anthracycline chemotherapy (n=24). Anthracycline chemotherapy vs. Baseline was evaluated on CMR left ventricular ejection fraction (LVEF) (p=<0.001). Anthracycline chemotherapy significantly reduced CMR left ventricular ejection fraction from 61% at baseline to 53% at completion of treatment, with baseline MAPSE and specific miRNAs predicting poor recovery.